PVLA PALVELLA THERAPEUTICS INC

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:

Cantor Global Healthcare Conference

Thursday, September 4, 2025, at 2:45pm ET

H.C. Wainwright 27th Annual Global Investment Conference

Monday, September 8, 2025, at 10:30am ET

A live webcast of both presentations will be available on the  section of Palvella's website at . An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit  or follow Palvella on  or  (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.



Contact Information

Investors

Wesley H. Kaupinen

Founder and CEO, Palvella Therapeutics



Media

Marcy Nanus

Managing Partner, Trilon Advisors, LLC



EN
28/08/2025

Underlying

PVLAPALVELLA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALVELLA THERAPEUTICS INC

 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Announces Scientific Publication in Lymphatic Re...

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations ...

8h / 51m 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of Q...

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with skin involvement impacting an estimated approximately 50-80% of patients, which can result in bleeding, thrombosis, ulceration, disfigurement, and proliferation QTORIN™ rapamycin has the potential to be the first approved th...

September 15, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Strengthens Leadership with Appointment of Accom...

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella...

September 3, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics to Present at Upcoming Healthcare Investor Confe...

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows: Cantor Global Healthcare Co...

August 28, 2025 1 EN
 PRESS RELEASE
Free
PVLA PALVELLA THERAP...

Palvella Therapeutics Reports Second Quarter 2025 Financial Results an...

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of c...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch